AgMedica Bioscience Inc. (“AgMedica” or the “Company”), a licensed producer (“LP”) of medicinal cannabis, is pleased to announce that it has increased its existing supply and distribution arrangements to include seven Canadian provinces and territories, and the Company continues to pursue further opportunities to extend its national reach.
In addition to its expansive cannabis supply and distribution capabilities across Canada, AgMedica became the youngest LP in the country to achieve current Good Manufacturing Practice (“cGMP”) certification, which was realized only one year after Health Canada granted the Company its first licence to cultivate. Internationally-recognized firm SGS carried out an independent third-party inspection of AgMedica’s processes and facilities against both the EU and Health Canada regulations for cGMP requirements. This certification positions AgMedica one step closer to shipping cannabis for medical purposes to the EU and other international countries.
With an expanding market presence across Canada, and the ability to secure new potential strategic partnerships with emerging markets, AgMedica continues to execute its vision of being a global leader in innovation and commercialization of cannabis-derived health and wellness solutions.
About AgMedica Bioscience Inc.
As a licensed producer of medicinal cannabis, AgMedica is dedicated to becoming a global leader in the development and commercialization of cannabis and cannabis-derived products to support the health and wellness of our clients. We aspire to drive the evolution of the cannabis industry by focussing investment on the development and commercialization of differentiated products in the medicinal, health & wellness and pharmaceutical sectors.
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance, results or offering of products. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. These risks and uncertainties include, but are not limited to, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.
SOURCE AgMedica Bioscience Inc.
For further information: please visit our website at www.agmedica.ca or contact: AgMedica Bioscience Inc., Sengkee Ahn, MBA, FEA, Vice President, Investor Relations and International Business Development, P: 1-844-247-4633, E: info@AgMedica.ca